BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1778 related articles for article (PubMed ID: 32264919)

  • 41. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
    Lin Y; Lin H; Xu Z; Zhou S; Chi P
    J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
    [No Abstract]   [Full Text] [Related]  

  • 42. Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
    Zhang J; Huang M; Cai Y; Wang L; Xiao J; Lan P; Hu H; Wu X; Ling J; Peng J; Chen D; Kang L; Zhang Y; Ren D; Wang H; Chen S; Lin F; Zheng J; Zhou Z; Wang J; Deng Y
    Clin Colorectal Cancer; 2019 Dec; 18(4):238-244. PubMed ID: 31378655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.
    Breugom AJ; van Gijn W; Muller EW; Berglund Å; van den Broek CBM; Fokstuen T; Gelderblom H; Kapiteijn E; Leer JWH; Marijnen CAM; Martijn H; Meershoek-Klein Kranenbarg E; Nagtegaal ID; Påhlman L; Punt CJA; Putter H; Roodvoets AGH; Rutten HJT; Steup WH; Glimelius B; van de Velde CJH
    Ann Oncol; 2015 Apr; 26(4):696-701. PubMed ID: 25480874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin and 5-fluorouracil after mesorectal excision with lateral pelvic lymph node dissection for stage iii lower rectal cancer.
    Iwasa S; Souda H; Yamazaki K; Takahari D; Miyamoto Y; Takii Y; Ikeda S; Hamaguchi T; Kanemitsu Y; Shimada Y
    Anticancer Res; 2015 Mar; 35(3):1815-9. PubMed ID: 25750348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial.
    Karoui M; Gallois C; Piessen G; Legoux JL; Barbier E; De Chaisemartin C; Lecaille C; Bouche O; Ammarguellat H; Brunetti F; Prudhomme M; Regimbeau JM; Glehen O; Lievre A; Portier G; Hartwig J; Goujon G; Romain B; Lepage C; Taieb J;
    Colorectal Dis; 2021 Jun; 23(6):1357-1369. PubMed ID: 33580623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
    Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A
    Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer.
    Akiyoshi T; Toda S; Tominaga T; Oba K; Tomizawa K; Hanaoka Y; Nagasaki T; Konishi T; Matoba S; Fukunaga Y; Ueno M; Kuroyanagi H
    BJS Open; 2019 Dec; 3(6):822-829. PubMed ID: 31832589
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
    Rahma OE; Yothers G; Hong TS; Russell MM; You YN; Parker W; Jacobs SA; Colangelo LH; Lucas PC; Gollub MJ; Hall WA; Kachnic LA; Vijayvergia N; O'Rourke MA; Faller BA; Valicenti RK; Schefter TE; George S; Kainthla R; Stella PJ; Sigurdson E; Wolmark N; George TJ
    JAMA Oncol; 2021 Aug; 7(8):1225-1230. PubMed ID: 34196693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial.
    Fan WH; Wang FL; Lu ZH; Pan ZZ; Li LR; Gao YH; Chen G; Wu XJ; Ding PR; Zeng ZF; Wan DS
    Chin J Cancer; 2015 Jun; 34(9):394-403. PubMed ID: 26111932
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The survival impact of preoperative FOLFOX for resectable locally advanced rectal cancer: the R-NAC-01 study.
    Ichikawa N; Homma S; Funakoshi T; Hattori M; Sato M; Kamiizumi Y; Omori K; Nomura M; Yokota R; Koike M; Kon H; Takeda K; Ishizu H; Matsuoka S; Hirose K; Ishikawa T; Murata R; Iijima H; Yoshida T; Minagawa N; Takahashi N; Taketomi A
    Surg Today; 2022 Aug; 52(8):1134-1142. PubMed ID: 34985549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.
    Zhang MX; Li XB; Guan BJ; Guan GX; Lin XY; Wu XD; Chi P; Xu BH
    BMJ Open; 2019 Mar; 9(3):e025944. PubMed ID: 30904869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial?
    Rödel C; Arnold D; Becker H; Fietkau R; Ghadimi M; Graeven U; Hess C; Hofheinz R; Hohenberger W; Post S; Raab R; Sauer R; Wenz F; Liersch T
    Strahlenther Onkol; 2010 Dec; 186(12):658-64. PubMed ID: 21136027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Neoadjuvant treatment for rectal cancer].
    Bachet JB; Benoist S; Mas L; Huguet F
    Bull Cancer; 2021 Sep; 108(9):855-867. PubMed ID: 34140155
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases.
    Cho H; Kim JE; Kim KP; Yu CS; Kim JC; Kim JH; Lee MA; Jang HS; Oh ST; Kim SY; Oh JH; Kim DY; Hong YS; Kim TW
    Am J Clin Oncol; 2016 Dec; 39(6):623-629. PubMed ID: 27322695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer.
    Fu XL; Fang Z; Shu LH; Tao GQ; Wang JQ; Rui ZL; Zhang YJ; Tian ZQ
    Oncotarget; 2017 May; 8(21):34340-34351. PubMed ID: 28423720
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial.
    Karoui M; Rullier A; Luciani A; Bonnetain F; Auriault ML; Sarran A; Monges G; Trillaud H; Le Malicot K; Leroy K; Sobhani I; Bardier A; Moreau M; Brindel I; Seitz JF; Taieb J
    BMC Cancer; 2015 Jul; 15():511. PubMed ID: 26156156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
    Seddik Y; Brahmi SA; Afqir S
    Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
    Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y
    BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
    Sastre J; Custodio A; Sanchez JC; Ortega L; Rodriguez L; Puente J; Corona J; Alfonso R; de las Heras M; Dıaz-Rubio E
    Anticancer Drugs; 2011 Feb; 22(2):185-90. PubMed ID: 21218606
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial.
    Liu L; Cao C; Zhu Y; Li D; Feng H; Luo J; Tang Z; Liu P; Lu K; Ju H; Zhang N
    Med Oncol; 2015 Mar; 32(3):70. PubMed ID: 25694046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 89.